Does Primary Hyperparathyroidism Have an Association with Thyroid Papillary Cancer? A Retrospective Cohort Study
To investigate the relationship between primary hyperparathyroidism (pHPT) and papillary thyroid cancer (PTC).
The perioperative findings of 275 patients with pHPT who underwent surgery between January 2014 and December 2017 were retrospectively reviewed. Thirty-one patients were diagnosed with pHPT and PTC concurrently. Pathology results and demographic findings of these patients were compared with 186 patients who underwent thyroidectomy and diagnosed with PTC at the same time interval.
The co-occurrence of pHPT and PTC was 11.3% (31/275). The median ages of the pHPT, pHPT + PTC, and PTC groups were 55, 57, and 50 years old, respectively (p < 0.001). The diameter of tumor was smaller in the pHPT + PTC group [median 7 mm (range 0.5–25 mm) vs. 15 mm (range 1–100 mm)], with higher rates of microcarcinomas (p < 0.001), than the patients in the PTC group. Examination of tumor morphology showed higher rates of tumor capsule invasion and multicentricity in the pHPT + PTC group than those in the isolated PTC group (p = 0.02, p = 0.04, respectively).
The pHPT + PTC group had significantly smaller tumor diameter than the PTC group. This result may support the idea that pHPT leads to overdiagnosis of PTC. However, observation of high rates of tumor capsule invasion and multicentricity in the pHPT + PTC group may suggest an associative etiology with more aggressive PTC.
Compliance with ethical standards
Conflict of interest
None of the authors have any financial or other relationship leading to a conflict of interest.
All procedures performed in studies involving human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Study protocol was approved by Dr. Lutfi Kirdar Kartal Research and Training Hospital in affiliation with University of Medical Sciences’ ethics committee.
Informed consent was not obtained from participants due to retrospective design of the study.
- 4.Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133CrossRefGoogle Scholar
- 5.Noone AM, Howlader N, Krapcho M et al (2018) SEER cancer statistics review, 1975–2015, National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Accessed 26 Sept 2018
- 11.Ogburn PL, Black BM (1956) Primary hyperparathyroidism and papillary adenocarcinoma of the thyroid: report of four cases. Proc Staff Meet Mayo Clin 31:295–298Google Scholar
- 14.Krause UC, Friedrich JH, Olbricht T, Metz K (1996) Association of primary hyperparathyroidism and non-medullary thyroid cancer. Eur J Surg (Acta Chir) 162:685–689Google Scholar
- 18.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): thyroid carcinoma. Version 1.2018. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed 10 June 2018
- 25.Cinamon U, Levy D, Marom T (2015) Is primary hyperparathyroidism a risk factor for papillary thyroid cancer? An exemplar study and literature review. Int Arch Otorhinolaryngol 19:42–45Google Scholar
- 28.Veselý D, Astl J, Matucha P, Sterzl I, Betka J (2003) Serum levels of angiogenic growth factors in patients with thyroid gland tumors and parathyroid adenoma. Neuro Endocrinol Lett 24:417–419Google Scholar